drugset / Trial / NCT00987844

Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation

NCT00987844

Phase 3 Completed 1775 enrolled Movetis
NaSingle-groupOpen-labelTreatment

Summary

Objectives: To evaluate the clinical long-term safety and the tolerability, patient satisfaction, pharmacokinetics and use of pattern of prucalopride given in doses up to 4 mg per day to patients with chronic constipation (CC).

Timeline

Start
1998-07
Primary completion
2000-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Prucalopride Small molecule 4 mg Oral

Indications